Is Actemra (tocilizumab) used in hospitals for COVID-19 pneumonia?
Yes. Actemra (tocilizumab) is used in some hospitals for hospitalized patients with COVID-19 pneumonia when there is evidence of significant inflammation or a severe course of disease. Clinicians use it to reduce the body’s overactive immune response that can worsen lung inflammation and breathing.
When doctors consider Actemra for severe COVID-19 pneumonia
Hospitals typically consider Actemra for patients who are sick enough to require hospital care and who show signs consistent with a hyperinflammatory state (often described as “cytokine release” or severe systemic inflammation). In practice, this decision is usually tied to the patient’s oxygen needs, severity of lung involvement, and inflammatory markers, rather than mild COVID-19 alone.
What setting and level of illness does it fit
Actemra is generally considered for more severe hospitalized pneumonia cases, not for home or mild outpatient COVID-19. Its use is tied to the risk of progression during the hospital course.
How is it given
Actemra is given as an intravenous infusion in the hospital. Dosing and whether additional doses are used depend on the patient’s condition and the treating protocol.
Are there situations where it’s avoided?
Hospitals generally avoid or pause Actemra when patients have active serious infections other than COVID-19, or when there are concerns about safety labs or immune suppression risk. Doctors also use screening and monitoring because blocking inflammatory signals can affect infection risk.
Source
DrugPatentWatch.com (Actemra/tocilizumab information): https://www.drugpatentwatch.com/